Overview
BioPharmaChem Ireland (BPCI) has launched its Budget 2026 submission, calling for Government to build sector resilience through strategic investment that enhance the competitiveness of the industry in Ireland and support the achievement of its sustainability goals.
With over 90 biopharmaceutical and pharmaceutical companies in Ireland, employing over 80,000 people directly and indirectly, the sector in Ireland is thriving. However, to maintain and further develop the sector's global leadership, sharpen its competitive edge and secure its future, BioPharmaChem Ireland is calling on Government to address the competitiveness challenges facing the industry.
.png?rev=adaac492d1244126b48fb675c297dcb1)
Explore / Our pillars
BioPharmaChem Ireland’s Budget 2026 submission outlines the critical importance of investments that are needed across five key pillars:
- Deliver a world-class innovation ecosystem
- Investing in skills and talent
- Support a resilient life sciences sector
- Strengthen regulatory capacity to safeguard competitiveness
- Accelerate the green transition by scaling renewable energy adoption
The upcoming BioPharmaChem Ireland Budget 2026 submission places skills and innovation at its core, emphasising the need for public investment and strategic collaboration across the ecosystem to unlock the sector’s full potential.
Listen to our podcasts
The upcoming BioPharmaChem Ireland Budget 2026 places Skills and Innovation at its core, echoing Ibec’s Business Ambition campaign for a competitive, productive and resilient economy. In this episode of Ibec Responds, Dr. Sinead Keogh, Director of Biopharmachem Ireland and Head of Ibec Sectors, is in conversation with Darrin Morrissey, CEO of NIBRT.
Dr Sinead Keogh, Director of BioPharmaChem Ireland and Ibec Head of Sectors, is joined by Jamie Guidera, interim COO at SSPC. Together, they explore the centre’s academic foundations, its powerful industry network, and how Ireland’s strategic positioning in a fast-moving global landscape of therapeutic discovery.